Interactive Features

Quiz

True or False: Ripretinib demonstrated meaningful clinical activity for gastrointestinal stromal tumors after first-line imatinib.

10/18/2022

Did ripretinib demonstrate meaningful clinical activity for patients with advanced gastrointestinal stromal tumors following progression on or intolerance to first-line imatinib? Take our quiz to find out.

Did ripretinib demonstrate...

10/18/2022

Oncology

Test Your Knowledge

Quiz: Is There Indication of Decreasing Prevalence of GISTs?

02/24/2022

True or false: Acknowledging GISTs are the most common sarcoma of the GI tract, with estimated incidence between 1.0 and 1.5/100,000 per year, current estimates suggest prevalence decreasing incidences.

True or false: Acknowledging...

02/24/2022

Oncology

Test Your Knowledge

Quiz: Is There Indication of Decreasing Prevalence of GISTs?

02/24/2022

True or false: Acknowledging...

02/24/2022

Oncology

Test Your Knowledge

02/18/2022

True or false: Typically, clinical trials or targeted therapies are recommended for patients with c-KIT and PDGFRA wild-type GIST who are unable to obtain multi-target protein tyrosine kinase inhibitors therapy.

True or false: Typically,...

02/18/2022

Oncology

Test Your Knowledge

02/18/2022

True or false: Typically,...

02/18/2022

Oncology

Quiz

Quiz: Which Diagnosis Method Provides Better Aid for Patients with GIST?

08/11/2021

Which method is confirmed to provide better aid in the diagnosis of GIST therapy?

Which method is confirmed to...

08/11/2021

Oncology

Quiz

Quiz: Is There a Correlation Between High-Risk GIST and Chromosomal Complexity?

08/10/2021

True or false: In localized, high-risk GIST, patients with chromosomal complexities have poor RFS.

True or false: In localized,...

08/10/2021

Oncology

Test Your Knowledge

Quiz: Genetic Vs Sporadic Diagnosis in GIST

05/03/2021

True or False: A genetic diagnosis yields benefit in gastrointestinal stromal tumor therapy by informing the patient and provider(s) of the possibility for other malignancies, suggested surveillance, management for other NF1 comorbidities,...

True or False: A genetic...

05/03/2021

Oncology

Test Your Knowledge

Quiz: How is Ripretinib Designed to Treat GIST?

04/07/2021

True or false: Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of KIT and PDGFRA mutations.

True or false: Ripretinib is a...

04/07/2021

Oncology

Test Your Knowledge

Quiz: Adjuvant Imatinib for High-Risk GIST

03/29/2021

True or false: Prolonged adjuvant imatinib therapy extends overall survival in patients with high-risk GIST.

True or false: Prolonged...

03/29/2021

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology